Publications
Detailed Information
Efficacy of Intranasal Administration of the Recombinant Endolysin SAL200 in a Lethal Murine Staphylococcus aureus Pneumonia Model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Ji Yun | - |
dc.contributor.author | Jun, Kang Il | - |
dc.contributor.author | Kang, Chang Kyung | - |
dc.contributor.author | Song, Kyoung-Ho | - |
dc.contributor.author | Choe, Pyoeng Gyun | - |
dc.contributor.author | Bang, Ji-Hwan | - |
dc.contributor.author | Kim, Eu Suk | - |
dc.contributor.author | Park, Sang Won | - |
dc.contributor.author | Kim, Hong Bin | - |
dc.contributor.author | Kim, Nam-Joong | - |
dc.contributor.author | Park, Wan Beom | - |
dc.contributor.author | Oh, Myoung-don | - |
dc.date.accessioned | 2024-04-26T01:03:01Z | - |
dc.date.available | 2024-04-26T01:03:01Z | - |
dc.date.created | 2020-01-30 | - |
dc.date.issued | 2019-04 | - |
dc.identifier.citation | Antimicrobial Agents and Chemotherapy, Vol.63 No.4, p. e02009-18 | - |
dc.identifier.issn | 0066-4804 | - |
dc.identifier.uri | https://hdl.handle.net/10371/199647 | - |
dc.description.abstract | SAL200 is derived from a phage endolysin and is a novel candidate drug for the treatment of Staphylococcus aureus infection. We investigated the efficacy of the recombinant endolysin SAL200 in a lethal murine pneumonia model. Lethal pneumonia was established by intranasally administering a methicillin-susceptible (Newman) or methicillin-resistant (LAC) S. aureus strain into BALB/c mice. The mice were treated with a single intranasal administration of SAL200 or phosphate-buffered saline at 2 h after S. aureus infection. The survival rates were recorded until 60 h after the bacterial challenge. The bacterial loads in the lungs and blood, histopathology of lung tissues, and serum cytokine levels were evaluated following the S. aureus challenge. The SAL200-treated group and control group exhibited 90% to 95% and 10% to 40% survival rates, respectively. The bacterial loads in the lungs of the SAL200-treated group were significantly lower by similar to 10-fold than those of the control group as early as 1 h after treatment. Histopathologic recovery of pneumonia was observed in the SAL200-treated mice. The cytokine levels were comparable between groups. These results suggest that direct administration of SAL200 into the lungs could be a potential adjunct treatment against severe pneumonia caused by S. aureus. | - |
dc.language | 영어 | - |
dc.publisher | American Society for Microbiology | - |
dc.title | Efficacy of Intranasal Administration of the Recombinant Endolysin SAL200 in a Lethal Murine Staphylococcus aureus Pneumonia Model | - |
dc.type | Article | - |
dc.identifier.doi | 10.1128/AAC.02009-18 | - |
dc.citation.journaltitle | Antimicrobial Agents and Chemotherapy | - |
dc.identifier.wosid | 000462474100025 | - |
dc.identifier.scopusid | 2-s2.0-85063663182 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | e02009-18 | - |
dc.citation.volume | 63 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Eu Suk | - |
dc.contributor.affiliatedAuthor | Park, Sang Won | - |
dc.contributor.affiliatedAuthor | Kim, Hong Bin | - |
dc.contributor.affiliatedAuthor | Kim, Nam-Joong | - |
dc.contributor.affiliatedAuthor | Park, Wan Beom | - |
dc.contributor.affiliatedAuthor | Oh, Myoung-don | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | BACTERIOPHAGE ENDOLYSINS | - |
dc.subject.keywordPlus | PHAGE ENDOLYSIN | - |
dc.subject.keywordPlus | RELEASE | - |
dc.subject.keywordPlus | CPL-1 | - |
dc.subject.keywordPlus | LYSIN | - |
dc.subject.keywordPlus | MICE | - |
dc.subject.keywordAuthor | SAL200 | - |
dc.subject.keywordAuthor | Staphylococcus aureus | - |
dc.subject.keywordAuthor | mice | - |
dc.subject.keywordAuthor | phage endolysin | - |
dc.subject.keywordAuthor | pneumonia | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.